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Abstract 29 
Background and Aim: Enteral nutrition is not commonly used for the treatment of adults 30 
with active Crohn’s disease, despite patient interest in nutrition-based alternatives to 31 
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corticosteroids and evidence of efficacy in paediatric Crohn’s disease. The aim of this study 32 
was to assess the impact of two different enteral nutrition regimens on disease symptoms, 33 
nutrition and inflammatory markers in young adults with active Crohn’s disease. 34 
Methods: A prospective non-randomized pilot study of adults aged 16 – 40 years with active 35 
Crohn’s disease on endoscopy or imaging was undertaken. Patients were sequentially 36 
recruited to use two weeks of exclusive enteral nutrition followed by either six weeks of 37 
exclusive enteral nutrition or partial enteral nutrition with usual diet. Assessments of disease 38 
symptoms, nutrition and inflammatory markers were undertaken at baseline and throughout 39 
the treatment.  40 
Results: Thirty-eight patients with active disease were recruited.  Thirty-two (84 %) patients 41 
completed two weeks of exclusive enteral nutrition and had significant improvements in 42 
disease symptoms (p=0.003), serum c-reactive protein (p=0.005), insulin-like growth factor-1 43 
(p=0.006) and faecal calprotectin (p = 0.028). During the following six weeks, 21 patients 44 
continued exclusive enteral nutrition (14 (67%) completed treatment) and 11 patients used 45 
partial enteral nutrition (9 (82%) completed treatment). Initial improvements in symptoms, c-46 
reactive protein and nutrition markers were sustained over the next six weeks on both 47 
treatments. Faecal calprotectin non-significantly increased in 5/9 patients who used partial 48 
enteral nutrition and at week eight faecal calprotectin was greater than 500µg/g in 9/14 and 49 
7/9 patients who used exclusive or partial enteral nutrition respectively. There was no 50 
significant difference in clinical outcomes between the two groups at week eight. 51 
Conclusion: Two weeks of exclusive enteral nutrition significantly improved disease 52 
symptoms, nutrition and inflammatory markers. Further treatment with exclusive or partial 53 
enteral nutrition maintained initial improvements.  54 
 55 
Keywords: Crohn’s disease, enteral nutrition, faecal calprotectin, IGF-1 56 
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Introduction 58 
Crohn’s disease (CD), an incurable inflammatory bowel disease, can develop at any age.[1] 59 
Intestinal inflammation may present clinically as abdominal pain, increased frequency of 60 
loose bowel motions, and/or biochemically with elevated serum and fecal inflammatory 61 
markers.[2] There are many pharmaceutical and surgical treatments for active CD.[3, 4] 62 
Nutrition based treatments, the most common being exclusive enteral nutrition (EEN), is 63 
recommended as a first line therapy to treat active paediatric CD.[5] EEN is now commonly 64 
used to treat active CD in children and adolescents in New Zealand (NZ),[6] Australia,[7] 65 
Asia,[8] Canada,[9] and Europe.[10] Adults with CD are interested in nutrition based 66 
alternatives to corticosteroids,[11] and EEN is regularly used in Japan,[12] and increasingly 67 
in China,[13] to treat adults with active CD. For adults living in Western countries, EEN is 68 
not currently recommended as a first line treatment for active CD.[2, 14]  69 
 70 
Previous studies of EEN to induce CD remission in adult patients have provided variable 71 
results.[15] One of the reasons cited for the variability in outcomes is the poor palatability of 72 
nutrition formulas and poorer adherence to the exclusive regimens.[15] Partial enteral 73 
nutrition (PEN) may help alleviate issues with adherence to EEN: this approach has been 74 
trailed in children and adolescents, again with variable results.[16-18]  75 
 76 
In the paediatric age group, EEN offers patients benefits over and above the induction of 77 
disease remission, including high rates of mucosal healing, which are not achieved with 78 
corticosteroids.[19] Faecal calprotectin (FC) has been suggested as a biomarker of mucosal 79 
healing due to its moderate correlation with endoscopic assessments of mucosal healing.[20, 80 
21] A few paediatric studies have reported changes in FC following EEN treatment[16, 22-81 
24] but no studies in adult cohorts have reported changes in FC consequent to EEN.     82 
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 83 
This study aimed to investigate the feasibility and effectiveness of EEN and a novel PEN 84 
regimen in young adults with active CD on symptoms of active disease and secondly to 85 
document the impact of these treatments on nutrition and inflammatory markers including 86 
FC.  87 
 88 
Materials and Methods 89 
Participants 90 
From May 2013 to December 2015 young adults with active CD aged 16 to 40 years old were 91 
invited, at the discretion of the consulting gastroenterologist, to choose between nutrition 92 
therapy or corticosteroids to treat active disease. Eligible patients had CD involving at least 93 
the ileum and were managed by gastroenterologists in Christchurch, NZ. Patients were 94 
excluded from the study if they had isolated colonic disease, active psychological illness or 95 
had taken corticosteroids in the last fortnight. Concomitant use of other CD medications did 96 
not limit eligibility, however use of corticosteroid medications was not permitted and patients 97 
on mesalazine, biological or thiopurine medications needed to be on an existing and stable 98 
dose and despite medication use still have active CD. Patients could be started on a 99 
maintenance of remission dose of thiopurine medication once established and after four 100 
weeks of EN treatment. Active disease was defined as active disease visible by endoscopy or 101 
radiology or an elevated FC. Eligible patients were referred to one registered dietitian who 102 
obtained their informed consent and managed their nutrition therapy treatment. Ethical 103 
approval was given by the NZ Northern B Health and Disability Ethics Committee (ethics 104 
reference 13/NTB/11) and the pilot clinical trial was registered with Australia New Zealand 105 
Clinical Trial Registry (trial number 363665).   106 
 107 
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Enteral nutrition treatments 108 
Patients were sequentially recruited to use two weeks of EEN followed by another six weeks 109 
of EEN or PEN. Patients recruited between May 2013 and February 2015 were offered only 110 
EEN and patients recruited from March to December 2015 were offered only EEN followed 111 
by PEN. Patients’ nutrition requirements were calculated using bioimpedance analysis basal 112 
metabolic rate multiplied by a physical activity factor.[25] Patients’ nutritional requirements 113 
were reviewed fortnightly according to weight change and appetite.   114 
 115 
EEN treatment required patients to drink multiple cartons (200 mL) of a polymeric 6.32 116 
kJ/ml (1.5 kcal/ml) oral nutritional formula (Ensure Plus, Abbott Laboratories, The 117 
Netherlands) daily.  In addition to the prescribed EN, patients were encouraged to drink 118 
additional fluids either as water and/or black unsweetened tea, coffee or herbal tea and avoid 119 
all other foods and fluids. EEN was initiated by gradually replacing meals and snacks with 120 
EN over a period of three days.  121 
 122 
PEN treatment comprised of EN plus one small meal per day (lunch or dinner) of solid food. 123 
Lunch and dinner were chosen because these meals are more likely to contain larger amounts 124 
of protein and vegetable fiber than breakfast and these meals are commonly shared with 125 
friends and/or family. The sharing of food with friends and family was an important aspect 126 
because, during the EEN intervention of this study, many patients anecdotally reported EEN 127 
to be socially isolating. Patients were encouraged to eat a balanced meal similar to their usual 128 
eating habits. After both eight week treatments patients reintroduced usual foods and fluids 129 
and reduced EN intake over a period of three days. 130 
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Assessments 132 
Patients were assessed by the dietitian at weeks 0, 2, 4, 6 and 8. At baseline, demographics, 133 
family history, disease phenotype and outcome data were collected. Assessments at all five 134 
study appointments included a serum inflammatory marker (CRP), serum nutrition markers 135 
(insulin-like growth factor-1 (IGF-1) and albumin, anthropometrics (body mass index 136 
(BMI)), intestinal inflammation biomarker (FC) and clinical disease activity (Harvey 137 
Bradshaw Index (HBI)).  138 
 139 
Serum CRP, albumin and IGF-1 were measured by Canterbury Health Laboratories, NZ 140 
using immunoturbidimetry, bromocresol purple assay kit (Abbott C series analyser) and the 141 
iSYS automated chemiluminescence immunoassay (Immunodiagnostic Systems, United 142 
Kingdom) respectively. FC was batch analyzed from stool stored at – 80°C using a 143 
commercial enzyme linked immunosorbent assay kit (BÜHLMANN fCAL, EK-CAL2, 144 
Switzerland) as per the manufacturer’s instructions. The kit test range was 60 -3600 µg/g. An 145 
elevated HBI was not an inclusion criteria to receive EN therapy, therefore improvements in 146 
symptom/activity scores were calculated rather than rates of disease remission. 147 
 148 
Dietary intake of any food or fluids was self-reported fortnightly. Patients using PEN were 149 
asked to provide examples of the meals that they had consumed for their one meal per day. 150 
Significant and continued deviations from the protocols resulted in withdrawal from the 151 
study. During EEN, non-habitual and small amounts of usual foods/fluids was assumed to 152 
have a negligible impact on average energy intake. Nutrient and energy intake during PEN 153 
was calculated from a three-day food record using a smart phone/tablet app Evernote©. 154 
Patients recorded their intake of food and fluids in real time with photographs of the meal and 155 
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any leftovers alongside text descriptions. This electronic food diary has been validated 156 
against a paper food diary in young children (unpublished data) but not in adult patients. 157 
Nutrient analysis of food records was completed using “Kai-culator” dietary assessment 158 
software (version 1.15c Department of Human Nutrition, University of Otago, NZ). 159 
 160 
Statistical analysis 161 
The results are presented as percentage of responses, medians and ranges. Many of the 162 
variables were not normally distributed therefore groups were compared using Mann-163 
Whitney U test, Wilcoxon matched-pairs signed rank test, Fisher’s exact test, and Chi-164 
squared test.  Statistical significance was present with p < 0.05. Statistical tests and graphs 165 
were prepared in Prism 6 version 6.05 (GraphPad Software Inc.). 166 
 167 
Results 168 
Baseline characteristics of the treatment groups 169 
Thirty-eight patients were referred for EN therapy. The first 25 patients were offered two 170 
weeks of EEN therapy followed by a further six weeks EEN and the following 13 patients 171 
were offered two weeks of EEN followed by six weeks of PEN. The two groups were similar 172 
at baseline with the exception of serum albumin which was significantly lower in the PEN 173 
group (Table 1).  174 
 175 
Patients who had a history of weight loss prior to starting EN treatment (n = 19) had a median 176 
IGF-1 SDS which was significantly lower (-1.00 SDS compared with 0.10 SDS, p = 0.01) 177 
than the median score of patients (n = 19) whose weight was stable prior to treatment. There 178 
was no difference (p = 0.588) in the median BMI, nor serum albumin (p = 0.239) of those 179 
who had, and had not, experienced recent weight loss.   180 
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 181 
Concurrent use of medication, except corticosteroids, was permitted. Eight patients were 182 
established on stable doses of medications at baseline but still had active disease (Table 1).  183 
No patients were started on mesalazine or biological medications during EN treatment.  184 
 185 
 186 
Adherence to treatments 187 
Figure 1 summarises the flow of patients through the study.  Thirty-eight patients started 188 
EEN but within a few days of starting, two patients elected to use corticosteroids instead of 189 
EEN and another four patients did not tolerate the EN formula (increased diarrhoea or 190 
nausea) and therefore did not successfully initiate EEN. After the first two weeks of treatment 191 
21 patients continued on EEN treatment. During the following six weeks, seven patients did 192 
not complete EEN treatment: one needed surgery for a small bowel perforation, one 193 
reintroduced usual diet at week five in response to work stress, one developed nausea, one 194 
deviated significantly from the protocol, one did not respond after four weeks, one had 195 
persistent diarrhoea which resolved after stopping the formula and one needed nasogastric 196 
tube feeding to meet nutritional requirements and when the tube split opted not to have 197 
another tube placed. After the initial two weeks of EEN 11 patients moved onto PEN 198 
treatment of which two patients did not complete the treatment: one patient, who had a small 199 
bowel perforation and was waiting for surgery, flared after introducing usual food and 200 
returned to EEN until the surgery could be performed, and one patient had not responded by 201 
week four and was changed to corticosteroid treatment.   202 
 203 
There was no significant difference in the proportion of patients who did not complete EEN 204 
compared with PEN treatment (p = 0.502). However, more adolescent patients (< 18 years 205 
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old) did not complete either EEN or PEN treatment than those aged over 18 years (8/15 206 
compared with 3/23, p = 0.012).   207 
 208 
Dietary intake 209 
All patients, except one, reported 100 % compliance with the EEN protocol during the first 210 
fortnight of treatment. Thereafter, self-reported intake of usual foods and fluids in the EEN 211 
group was minimal, as was intake of foods and fluids apart from the one small meal during 212 
PEN treatment. Individuals’ total energy intake 6 276 – 13 807 kJ/day (1 500 – 3 300 213 
kcal/day), percentage of estimated energy requirements (% EER) and energy intake per 214 
weight varied widely (Table 2) as did the amount of physical activity. The one meal per day 215 
during PEN typically consisted of a protein food (red meat, chicken, eggs or fish) with a 216 
carbohydrate food (bread, rice, potato, sweet potato or pasta) and cooked or raw vegetables.   217 
 218 
Clinical outcomes 219 
During the first two weeks of EEN (n =32) median HBI fell from five to three points (p = 220 
0.003), median serum CRP fell from 10 mg/L to 5 mg/L (p = 0.005), median FC fell from 221 
927 µg/g to 674 µg/g (p = 0.028), median IGF-1 standard deviation score improved from 0.0 222 
to 0.05 (p = 0.006) and median serum albumin was unchanged at 39.5 g/L  (Figure 2).   223 
 224 
Fourteen patients used EEN for another six weeks after the initial two weeks of EEN. The 225 
improvements in inflammatory markers observed during the first two weeks were sustained 226 
to week 8 and there was further improvement in the median HBI (p = 0.031). At week 8, 5/14 227 
(36 %) patients had a FC < 500 µg/g compared with 4/14 (29 %) at baseline. Patients using 228 
EEN lost weight during treatment, the median BMI fell from 23.7 to 23.3 kg/m2 (W = -79, p 229 
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= 0.01) although the minimum BMI increased from 18.5 kg/m2 to 19.8 kg/m2 and nutrition 230 
markers serum IGF-1 and albumin improved during EEN treatment (Figure 3). 231 
 232 
Nine patients used PEN after an initial two weeks of EEN. The median HBI, CRP and FC 233 
remained stable after PEN treatment although FC increased in 5/9 patients during PEN 234 
treatment (Figure 2) and 2/9 (22 %) had a FC less than 500 µg/g compared with 3/9 (33 %) of 235 
patients at baseline. Clinical outcomes in the nine PEN patients were not correlated with 236 
volume of EN consumed nor the percentage of total energy from solid food.  Patients using 237 
PEN had a minimal change in median BMI from 25.2 to 24.7 kg/m2 (p > 0.05) and the 238 
minimum BMI increased from 16.5 kg/m2 to 18.5 kg/m2. 239 
 240 
There were no significant differences in disease activity nor nutrition or inflammatory 241 
markers at week eight between patients who used EEN for eight weeks compared with 242 
patients who used two weeks of EEN followed by six weeks of PEN.  243 
 244 
Discussion 245 
This prospective non-randomized pilot clinical trial of EEN and PEN is one of the first PEN 246 
studies to include only adults with active CD. This study used a novel PEN regimen which 247 
included two weeks of EEN followed by six weeks of PEN with one small meal of usual 248 
food. Three studies have been published which used PEN to treat active CD. One of these 249 
studies of PEN, which did not include an EEN control group, found that PEN with a specific 250 
food exclusion diet effectively induced disease remission in 70 % of children and adults.[18] 251 
Whereas, two of the studies found that EEN was superior to PEN with a free diet.[16, 17] In 252 
contrast, this study found that PEN with usual food resulted in similar outcomes to EEN at 253 
week eight. The lack of difference between the PEN and EEN treatments may be due to the 254 
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use of two weeks of EEN prior to the reintroduction of usual food. During the first two weeks 255 
of EEN patients had significant improvements in disease activity and inflammatory markers, 256 
such early improvements have been observed previously in the adult EEN literature.[13, 26, 257 
27]  Further, there is some evidence that patients with newly diagnosed disease respond better 258 
to nutrition therapy than patients with long standing intestinal inflammation.[28] The 259 
inclusion of mostly newly diagnosed patients and those with mild disease symptoms may 260 
have contributed to the comparable outcomes between the two treatments.  261 
 262 
Serum IGF-1 is a marker of nutrition status and has been suggested as a marker of disease 263 
activity[29, 30] due to its reduced expression in the presence of pro-inflammatory 264 
cytokines.[31] An early rise in IGF-1 subsequent to EEN treatment has previously been 265 
documented in paediatric IBD studies[30, 32] but has not been reported in adults with CD.  266 
Both paediatric studies concluded that early improvements in IGF-1 concentration were due 267 
to reduced inflammation rather than purely an improvement in nutrition intake. In this study 268 
median serum IGF-1 concentrations increased significantly after two weeks of treatment 269 
despite suboptimal caloric intake and reductions in BMI, and corresponded with a reduction 270 
in serum CRP and FC. These results support the paediatric IBD observations that IGF-1 is 271 
more than just a marker of nutrition status and that improvements in serum IGF-1 272 
concentration may also reflect reduced inflammation. 273 
 274 
FC has been suggested as a reliable non-invasive measure of endoscopic disease activity[20, 275 
21, 33, 34] but cut-off concentrations to distinguish active from inactive inflammation remain 276 
controversial.[20] Some paediatric studies have reported improvements in FC following 277 
EEN[22-24] but to date there are no reports of FC changes consequent to EEN or PEN in 278 
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adult cohorts. The current study found a non-significant trend towards improved FC after two 279 
weeks of EEN but further treatment with EEN did not result in further improvement in FC 280 
concentration. Paediatric EEN studies have also observed that FC often remains elevated post 281 
EEN treatment.[22, 24, 35] One PEN study has reported FC, they observed that 14 % 282 
children treated with PEN had a FC less than 250 µg/g compared with 45 % treated with 283 
EEN and 62 % treated with a biologic medication.[16] Their results, along with the those 284 
presented here, suggest that the inclusion of usual food with EN may limit gut mucosal 285 
healing.  286 
 287 
Patient withdrawal from EN treatment is common in many of the published adult studies and 288 
was previously associated with poor palatability of the nutrition formula.[15]  This study 289 
used a more palatable polymeric formula and as a result no patients withdrew from the 290 
treatment due to unpalatable formula. However, non-completion of treatment was higher than 291 
anticipated. Most (78 %) of the study cohort were female and 30 % were less than 18 years 292 
old. It has previously been suggested that female adolescents with IBD find EN therapy more 293 
attractive than corticosteroid treatment, due to the potential negative impact of CS treatment 294 
on body image.[36]  The high proportion of female participants may represent a selection 295 
bias because patients were referred to the study at the discretion of the consulting 296 
gastroenterologist rather than systematic referral of all patients meeting the study inclusion 297 
criteria.  The high proportion of female patients and secondary school age patients is likely to 298 
have affected treatment completion.   Females and older adolescents are more likely to 299 
withdraw from treatment due to non-adherence[10] and this trend was observed in the current 300 
study whereby 73 % of adolescents did not complete EN treatment compared with only 26 % 301 
of young adults aged 18 years and older. EN treatment may be a more acceptable treatment 302 
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for patients who have finished secondary education and moved into the workforce or tertiary 303 
education. 304 
 305 
A limitation of this study may be the lack of a non-EN control group. Previous randomized 306 
controlled trials of EEN and corticosteroids in paediatric patients have shown the two 307 
treatments have comparable efficacy[15, 37] whereas, intention to treat analysis in adult 308 
cohorts have found corticosteroids to be superior to EEN,[26, 38, 39] however, per protocol 309 
outcomes may be more similar.[15] The aim of this study was not to repeat previous research 310 
but to assess the feasibility and effectiveness of EEN and a combined EEN and PEN regimen. 311 
These pilot study results cannot be compared directly with the current standard treatment for 312 
mild to moderate adult CD, but the outcomes are of interest to patients and clinicians 313 
interested in trialing nutrition-based treatments. 314 
 315 
 316 
No single CD treatment is effective for all patients; like-wise nutrition-based therapies are 317 
unlikely to be appropriate for all patients either. For patients who are interested in using a 318 
nutritional approach, or who want to avoid using corticosteroids, EEN and PEN therapies are 319 
a feasible treatment option. In these modest cohorts of young adults with active CD, the data 320 
indicate that EEN effectively reduces clinical symptoms and markers of inflammation within 321 
the first two weeks of treatment. Further investigation into the potential role of a PEN 322 
regimen after an initial period of EEN is warranted, however, the composition of the food 323 
included in the regimen needs further investigation as does the impact of solid food on FC 324 
and mucosal healing. EN therapy is a feasible and effective option to treat active CD in 325 
young adults who have finished secondary education and could be offered to patients 326 
interested in using a nutritional therapy approach.    327 
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Figure Legends 442 
Figure 1. Flow chart of patients treated with exclusive and partial enteral nutrition. 443 
EEN, exclusive enteral nutrition; EN, enteral nutrition; PEN, partial enteral nutrition 444 
 445 
Figure 2. Clinical parameters at baseline and after two weeks exclusive enteral nutrition 446 
treatment (n = 33). 447 
CRP, c-reactive protein; EEN, exclusive enteral nutrition; IGF-1, insulin-like growth factor-1 448 
  449 
Figure 3. Clinical parameters at baseline, week 2 and week 8 of treatment of patients treated 450 
only with exclusive enteral nutrition or with two weeks of exclusive followed by six weeks of 451 
partial enteral.  452 
CRP, c-reactive protein; EEN, exclusive enteral nutrition; IGF-1, insulin-like growth factor-453 
1; PEN, partial enteral nutrition 454 
 455 
